![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, December 20, 2021 1:59:50 PM
In the early winter of 21, NVAX was trading in the $3 range, as we are. They have an enviable share structure, but our OS is even lower. They were the front-runner vaccine, as we are the front-runner therapeutic.
By May of 21, NVAX was trading at $46. Just over a year from when they were trading in the $3 range, they reached what remains their all-time high of over $300.
As dangerous as Covid was to the world last year, without vaccines, I think it is even more dangerous now, with ineffective vaccines. And only our patent-protected lenz will prevent disease progression of hospitalized and hypoxic patients.
I was hoping for some news this morning from Durrant regarding Kessler procuring all the lenz we could supply to the White House Covid task force.
I remain optimistic...but extremely anxious, as well. Come on, Cameron, stick the landing. And if they don't want to pay what we will be getting from Europe, I don't think they should, anyway. They need to pay more for causing the dilution of our share value.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM